Oligos & Peptides Formulation & Process Development

The inaugural Oligos & Peptides Formulation & Process Development Summit is the industry’s first forum bringing together experts addressing challenges and seek solutions to help to expedite drug discovery to scalable, GMP manufacturing for this new frontier of medicines!

Recently, Biogen’s announcement of $60m upfront investment on a new antisense candidate from Ionis, and Janssen’s strategic collaboration with i2O Therapeutics for macromolecules, demonstrated drug developers’ interest in next generation complex oligonucleotides and peptides have reached unprecedented level.

With the emergence of liquid phase synthesis technologies, improved bioavailability, and delivery approaches of oligos and peptides, drug developers realize the therapeutic potential of this 2nd generation of macromolecules can go beyond rare diseases with commercial viability.

Join 60+ of your peers and be part of this growing community. Featuring exclusive presentations, hands-on workshops, hours of networking from 18+ oligo and peptide thought-leaders, this summit will share exclusive insights on:

QbD for winning formula to optimize process development for complex oligos & peptides’

Synthesis strategies to improve stability of DS and DP

Updates on regulatory and CMC compliance

Seamless scale-up and tech transfer in collaboration with your CDMO partners

Prices:
Drug Developer Pricing - Conference + 2 Workshops USD 4297.00
Drug Developer Pricing - Conference + 1 Workshop USD 3648.00
Drug Developer Pricing - Conference Only USD 2999.00
Academic Research Institute Pricing - Conference + 2 Workshops USD 3697.00
Academic Research Institute Pricing - Conference + 1 Workshop USD 3148.00
Academic Research Institute Pricing - Conference Only USD 2599.00
Service Provider Pricing - Conference + 2 Workshops USD 5097.00
Service Provider Pricing - Conference + 1 Workshop USD 4348.00
Service Provider Pricing - Conference Only USD 3599.00

Speakers: Ranajoy Majumdar, Director – Analytical Development, Eli Lilly & Company, Nadim Akhatar, Senior Principal Scientist, New Modalities, AstraZeneca, Oliver Thiel, Executive Director Process Development, Drug Substance Technologies Pivotal & Commercial Synthetics, Amgen, Rob Shaffer, Founder/COO, Vrata Therapeutics, Ashish Garg, Director of Engineering, Eli Lilly & Company, Bob Duff, Senior Director, Medicine Chemistry, Switch Therapeutics, Tim Turner, Senior Manager, Synthetic Process Development, Alexion Pharmaceuticals, Michael Hellerstein, VP Product Development, Vaxxinity, Prof Dimitrios A. Lamprou, Professor, Queens University Belfast, Zhongping Liao, Sr. Advisor, Eli Lilly & Company, Rajendra K Pandey, Vice President, Chemistry, Cargene Therapeutics, Laure-Elie Carloni, Senior Scientist – Group Leader, Janssen, Nigel Richardson, Technical Director, CatSci Ltd, Gordon Lambertus, Principal Research Scientist, Eli Lilly & Company, Tomas Leek, Director, AstraZeneca, Naresh Badgujar, Associate Principal Scientist, AstraZeneca, Susan Rosenbaum, Founder, Chairman, CEO, Lauren Sciences LLC, Marc Lemaitre, Principal, ML Consult, Mike Webb, Founder & CEO, Mike Webb Pharma

Others Details

Brochure https://go.evvnt.com/1146643-3?pid=6581